TY - JOUR AU - Slamon, D. J. AU - Clark, G. M. AU - Wong, S. G. AU - Levin, W. J. AU - Ullrich, A. AU - McGuire, W. L. PY - 1987 DA - 1987// TI - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene JO - Science VL - 235 UR - https://doi.org/10.1126/science.3798106 DO - 10.1126/science.3798106 ID - Slamon1987 ER - TY - JOUR AU - Slamon, D. J. AU - Godolphin, W. AU - Jones, L. A. AU - Holt, J. A. AU - Wong, S. G. AU - Keith, D. E. AU - Levin, W. J. AU - Stuart, S. G. AU - Udove, J. AU - Ullrich, A. PY - 1989 DA - 1989// TI - Studies of the HER-2/Neu proto-oncogene in human breast and ovarian cancer JO - Science VL - 244 UR - https://doi.org/10.1126/science.2470152 DO - 10.1126/science.2470152 ID - Slamon1989 ER - TY - JOUR AU - Ross, J. S. AU - Fletcher, J. A. AU - Linette, G. P. AU - Stec, J. AU - Clark, E. AU - Ayers, M. AU - Symmans, W. F. AU - Pusztai, L. AU - Bloom, K. J. PY - 2003 DA - 2003// TI - The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy JO - Oncologist VL - 8 UR - https://doi.org/10.1634/theoncologist.8-4-307 DO - 10.1634/theoncologist.8-4-307 ID - Ross2003 ER - TY - JOUR AU - De Laurentiis, M. AU - Arpino, G. AU - Massarelli, E. AU - Ruggiero, A. AU - Carlomagno, C. AU - Ciardiello, F. AU - Tortora, G. AU - D'Agostino, D. AU - Caputo, F. AU - Cancello, G. AU - Montagna, E. AU - Malorni, L. AU - Zinno, L. AU - Lauria, R. AU - Bianco, A. R. AU - De Placido, S. PY - 2005 DA - 2005// TI - A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2569 DO - 10.1158/1078-0432.CCR-04-2569 ID - De Laurentiis2005 ER - TY - JOUR AU - Cobleigh, M. A. AU - Vogel, C. L. AU - Tripathy, D. AU - Robert, N. J. AU - Scholl, S. AU - Fehrenbacher, L. AU - Wolter, J. M. AU - Paton, V. AU - Shak, S. AU - Lieberman, G. AU - Slamon, D. J. PY - 1999 DA - 1999// TI - Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease JO - J Clin Oncol VL - 17 ID - Cobleigh1999 ER - TY - JOUR AU - Vogel, C. L. AU - Cobleigh, M. A. AU - Tripathy, D. AU - Gutheil, J. C. AU - Harris, L. N. AU - Fehrenbacher, L. AU - Slamon, D. J. AU - Murphy, M. AU - Novotny, W. F. AU - Burchmore, M. AU - Shak, S. AU - Stewart, S. J. AU - Press, M. PY - 2002 DA - 2002// TI - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.3.719 DO - 10.1200/JCO.20.3.719 ID - Vogel2002 ER - TY - JOUR AU - Marty, M. AU - Cognetti, F. AU - Maraninchi, D. AU - Snyder, R. AU - Mauriac, L. AU - Tubiana-Hulin, M. AU - Chan, S. AU - Grimes, D. AU - Antón, A. AU - Lluch, A. AU - Kennedy, J. AU - O'Byrne, K. AU - Conte, P. AU - Green, M. AU - Ward, C. AU - Mayne, K. AU - Extra, J. M. PY - 2005 DA - 2005// TI - Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.04.173 DO - 10.1200/JCO.2005.04.173 ID - Marty2005 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. AU - Fleming, T. AU - Eiermann, W. AU - Wolter, J. AU - Pegram, M. AU - Baselga, J. AU - Norton, L. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Pietras, R. J. AU - Pegram, M. D. AU - Finn, R. S. AU - Maneval, D. A. AU - Slamon, D. J. PY - 1998 DA - 1998// TI - Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs JO - Oncogene VL - 17 UR - https://doi.org/10.1038/sj.onc.1202132 DO - 10.1038/sj.onc.1202132 ID - Pietras1998 ER - TY - JOUR AU - Pegram, M. AU - Hsu, S. AU - Lewis, G. AU - Pietras, R. AU - Beryt, M. AU - Sliwkowski, M. AU - Coombs, D. AU - Baly, D. AU - Kabbinavar, F. AU - Slamon, D. PY - 1999 DA - 1999// TI - Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers JO - Oncogene VL - 18 UR - https://doi.org/10.1038/sj.onc.1202526 DO - 10.1038/sj.onc.1202526 ID - Pegram1999 ER - TY - JOUR AU - Tripathy, D. AU - Hassan, S. AU - Verma, S. AU - Gurnani, P. AU - Nandi, A. AU - Rosenblatt, K. PY - 2005 DA - 2005// TI - Phenotypic and proteomic alterations of acquired trastuzumab resistance JO - J Clin Oncol VL - 23 ID - Tripathy2005 ER - TY - STD TI - Shirane M, Fujimoto-Ouchi K, Sekiguchi F, Nunomura K, Mori K: Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Eur J Cancer. 2005, 115-Supplement 3 ID - ref12 ER - TY - JOUR AU - Nahta, R. AU - Esteva, F. J. PY - 2004 DA - 2004// TI - In vitroeffects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells JO - Cancer Chemother Pharmacol VL - 53 UR - https://doi.org/10.1007/s00280-003-0728-3 DO - 10.1007/s00280-003-0728-3 ID - Nahta2004 ER - TY - JOUR AU - Bartsch, R. AU - Wenzel, C. AU - Hussian, D. AU - Pluschnig, U. AU - Sevelda, U. AU - Koestler, W. AU - Altorjai, G. AU - Locker, G. J. AU - Mader, R. AU - Zielinski, C. C. AU - Steger, G. G. PY - 2006 DA - 2006// TI - Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study JO - BMC Cancer VL - 6 UR - https://doi.org/10.1186/1471-2407-6-63 DO - 10.1186/1471-2407-6-63 ID - Bartsch2006 ER - TY - JOUR AU - Extra, J. -. M. AU - Antoine, E. -. C. AU - Vincent-Salomon, A. AU - Bergougnoux, L. AU - Campana, F. AU - Namer, M. PY - 2006 DA - 2006// TI - Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study JO - Breast Cancer Res Treat VL - 100 ID - Extra2006 ER - TY - JOUR AU - Fountzilas, G. AU - Razis, E. AU - Tsavdaridis, D. AU - Karina, M. AU - Labropoulos, S. AU - Christodoulou, C. AU - Mavroudis, D. AU - Gogas, H. AU - Georgoulias, V. AU - Skarlos, D. PY - 2003 DA - 2003// TI - Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group JO - Clin Breast Cancer VL - 4 UR - https://doi.org/10.3816/CBC.2003.n.017 DO - 10.3816/CBC.2003.n.017 ID - Fountzilas2003 ER - TY - JOUR AU - Garcia-Saenz, J. AU - Martin, M. AU - Bueno, C. AU - Sampedro, T. AU - Lopez-Tarruella, S. AU - Puente, J. AU - Villalobos, L. AU - Rodriguez, L. AU - Garcia, B. AU - Casado, A. AU - Diaz-Rubio, E. PY - 2005 DA - 2005// TI - Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer JO - Clin Breast Cancer. VL - 6 UR - https://doi.org/10.3816/CBC.2005.n.035 DO - 10.3816/CBC.2005.n.035 ID - Garcia-Saenz2005 ER - TY - JOUR AU - Gelmon, K. A. AU - Mackey, J. AU - Verma, S. AU - Gertler, S. Z. AU - Bangemann, N. AU - Klimo, P. AU - Schneeweiss, A. AU - Bremer, K. AU - Soulieres, D. AU - Tonkin, K. AU - Bell, R. AU - Heinrich, B. AU - Grenier, D. AU - Dias, R. PY - 2004 DA - 2004// TI - Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories JO - Clin Breast Cancer VL - 5 UR - https://doi.org/10.3816/CBC.2004.n.010 DO - 10.3816/CBC.2004.n.010 ID - Gelmon2004 ER - TY - JOUR AU - Metro, G. AU - Mottolese, M. AU - Di Cosimo, S. AU - Papaldo, P. AU - Ferretti, G. AU - Carlini, P. AU - Cianciulli, A. M. AU - Giannarelli, D. AU - Cognetti, F. AU - Fabi, A. PY - 2007 DA - 2007// TI - Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC) JO - J Clin Oncol VL - 25 ID - Metro2007 ER - TY - JOUR AU - Montemurro, F. AU - Donadio, M. AU - Clavarezza, M. AU - Redana, S. AU - Jacomuzzi, M. E. AU - Valabrega, G. AU - Danese, S. AU - Vietti-Ramus, G. AU - Durando, A. AU - Venturini, M. AU - Aglietta, M. PY - 2006 DA - 2006// TI - Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy JO - Oncologist VL - 11 UR - https://doi.org/10.1634/theoncologist.11-4-318 DO - 10.1634/theoncologist.11-4-318 ID - Montemurro2006 ER - TY - JOUR AU - Stemmler, H. J. AU - Kahlert, S. AU - Siekiera, W. AU - Untch, M. AU - Heinrich, B. AU - Heinemann, V. PY - 2005 DA - 2005// TI - Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) JO - Onkologie VL - 28 ID - Stemmler2005 ER - TY - JOUR AU - Tripathy, D. AU - Slamon, D. J. AU - Cobleigh, M. AU - Arnold, A. AU - Saleh, M. AU - Mortimer, J. E. AU - Murphy, M. AU - Stewart, S. J. PY - 2004 DA - 2004// TI - Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.06.557 DO - 10.1200/JCO.2004.06.557 ID - Tripathy2004 ER - TY - JOUR AU - Geyer, C. E. AU - Forster, J. AU - Lindquist, D. AU - Chan, S. AU - Romieu, C. G. AU - Pienkowski, T. AU - Jagiello-Gruszfeld, A. AU - Crown, J. AU - Chan, A. AU - Kaufman, B. AU - Skarlos, D. AU - Campone, M. AU - Davidson, N. AU - Berger, M. AU - Oliva, C. AU - Rubin, S. D. AU - Stein, S. AU - Cameron, D. PY - 2006 DA - 2006// TI - Lapatinib plus capecitabine for HER2-positive advanced breast cancer JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa064320 DO - 10.1056/NEJMoa064320 ID - Geyer2006 ER - TY - STD TI - GBG German Breast Group, Herceptin – TBP [in German]. [http://www.germanbreastgroup.de/herceptin] UR - http://www.germanbreastgroup.de/herceptin ID - ref24 ER - TY - STD TI - A Study of Herceptin (Trastuzumab) in Combination with 2nd-Line Chemotherapy in Patients with HER2 Positive Metastatic Breast Cancer. [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=539603&version=HealthProfessional&protocolsearchid=3577090] UR - http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=539603&version=HealthProfessional&protocolsearchid=3577090 ID - ref25 ER - TY - STD TI - THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=542712&version=HealthProfessional&protocolsearchid=3577090] UR - http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=542712&version=HealthProfessional&protocolsearchid=3577090 ID - ref26 ER - TY - JOUR AU - Von Minckwitz, G. AU - Zielinski, C. AU - Maarteense, E. AU - Vogel, P. AU - Schmidt, M. AU - Eidtmann, H. AU - Cufer, T. AU - de Jongh, F. E. AU - Kaufmann, M. AU - Loibl, S. PY - 2008 DA - 2008// TI - Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) [abstract] JO - J Clin Oncol VL - 26 ID - Von Minckwitz2008 ER -